Kerr Douglas 4
4 · Dyne Therapeutics, Inc. · Filed Jun 17, 2026
Research Summary
AI-generated summary of this filing
Dyne Therapeutics (DYN) CMO Kerr Douglas Sells Shares
What Happened Kerr Douglas, Chief Medical Officer of Dyne Therapeutics (DYN), sold 887 shares in an open-market/private sale on June 16, 2026. The weighted average sale price was $18.33 per share for a total of approximately $16,259. The sale was an automatic disposition to satisfy tax-withholding obligations tied to the vesting of restricted stock units (RSUs).
Key Details
- Transaction date: 2026-06-16 (reported on Form 4 filed 2026-06-17) — appears timely.
- Transaction type: Sale (S) of 887 shares; weighted average price $18.33; reported price range $18.00–$18.70 across multiple trades.
- Total proceeds: ~$16,259.
- Reason/footnote: Automatic sale to satisfy tax withholding on RSU vesting (per RSU agreement); characterized as a non-discretionary sale consistent with a Rule 10b5-1 affirmative defense (Footnote F1).
- Holdings note: Footnote F3 states 145,313 unvested RSUs are included in reported holdings.
- Filing specifics: F2 notes the reported price is a weighted average and the filer can provide per-trade price details on request.
Context This was a routine, tax-withholding sale tied to RSU vesting rather than a discretionary sale motivated by trading decisions. Such automatic withholding dispositions are common and do not necessarily signal insider sentiment about the company.
Insider Transaction Report
Form 4
Kerr Douglas
Chief Medical Officer
Transactions
- Sale
Common Stock
[F1][F2][F3]2026-06-16$18.33/sh−887$16,259→ 169,155 total
Footnotes (3)
- [F1]Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
- [F3]Includes 145,313 unvested RSUs.
Signature
/s/ Ron Caponigro, Attorney-in-Fact|2026-06-17